Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.81 |
| ▸ | LCK | P06239 | 4/20 | 0.81 |
| ▸ | LYN | P07948 | 2/20 | 0.81 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.75 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | TEK | Q02763 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.68 |
| ▸ | ITK | Q08881 | 2/20 | 0.66 |
| ▸ | TEC | P42680 | 2/20 | 0.66 |
| ▸ | BMX | P51813 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | YES1 | P07947 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
| ▸ | FGR | P09769 | 1/20 | 0.66 |
| ▸ | FER | P16591 | 1/20 | 0.66 |
| ▸ | CSK | P41240 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22721026 | 0.94 | BTK (0.74) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22230575 | 0.94 | BTK (0.74) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243265 | 0.91 | BTK (0.67) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL6430471 | 0.90 | BTK (0.66) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL7001713 | 0.90 | BTK (0.81) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL5804534 | 0.90 | BTK (0.77) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL6431516 | 0.89 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL30586962 | 0.89 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL6431891 | 0.89 | BTK (0.66) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22720868 | 0.89 | BTK (0.71) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-113999233-A | BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2878601-A1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | Riken (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | BTK 42/4885LCK 1/4885LYN 72/4885 |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | BTK 2/4885LCK 7/4885LYN 3/4885 |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | ABL1, BTK, LYN | BTK 2/4885LCK 7/4885LYN 3/4885 |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, BCOR, RUNX1 | BTK 3219/4885LCK 3635/4885LYN 2032/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885LCK 1011/4885LYN 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.